Introduction {#sec1-1}
============

Allogenic red cell transfusion is safer now than it has ever been. Increasingly, restrictive policies covering who may donate blood, increased and more sensitive testing of donated blood for evidence of transmissible infectious agents, and increased vigilance surrounding the process of transfusion have contributed to this improved safety. However each and every blood transfusion have potential risk of transmitting transfusion transmitted infections and adverse transfusion reactions resulting from alloimmunization against red cell antigen or other cellular blood components. Therefore, protection of recipient from adverse transfusion reactions due to alloimmunization against red cell antigen is one of the challenge against safe blood transfusion. Immunization to red cell antigens may result from pregnancy, transfusion, transplantation, or injections of immunogenic material. In some instances, no specific immunizing event can be identified. Antibodies detected in serologic tests may be passively acquired. These antibodies may be acquired from injected immunoglobulin (Ig), donor plasma, passenger lymphocytes in transplanted organs, or hematopoietic progenitor cells.\[[@ref1][@ref2]\]

The degree of clinical significance varies among antibody of same specificity; some cause destruction of incompatible red cells within hours or even minutes whereas others cause a decrease in the red cell survival by only a few days and still others cause no discernible shortened red cell survival.

Some antibodies are known to cause hemolytic disease of fetus and newborn (HDFN) whereas others may cause a positive direct antiglobulin test (DAT) in the fetus without clinical evidence of HDFN. Clinically significant antibodies are usually IgG antibodies that react at 37°C or in the antihuman globulin phase of the DAT.\[[@ref1][@ref2]\]

This study is aimed at assessing the frequency and type of unexpected red cell antibodies in the general patient population and donors at a tertiary care teaching hospital in Western India. This would help in selection of appropriate unit for transfusion, investigating for causes of hemolytic anemia, investigating for causes of HDFN, preventing any transfusion reaction, and preventing any serological changes during pregnancy by providing anti-D to patients.

Materials and Methods {#sec1-2}
=====================

The study was carried out at the red cell serology laboratory of our Department of Immunohematology and Blood Transfusion, over a period of 2 years from January 2015 to December 2016. Blood samples collected in ethylenediaminetetraacetic acid (EDTA) and plain vacutainer from all patients and EDTA and plain vacutainer (Pilot tubes) from all donors were processed for ABO and Rh (D) blood grouping as well as antibody screening with the three cell panel on fully automated immunohematology analyzer "Qwalys-3" (Manufacturer: Diagast, France) working on the principle on erythrocyte magnetization technology. Samples giving positive antibody screen on three cell screening panel were subjected to antibody identification by extended eleven cell panel by column agglutination technology (Dia Med ID microtyping system-Bio-rad, USA). Any sample positive for antibody screening with the three cell panel on Qwalys-3 was subjected for repeat antibody screening by column agglutination technology (Gel card method) in commercially available three cell panel (Bio-Rad).

Data were examined to calculate the frequency of unexpected alloantibodies.

Results {#sec1-3}
=======

During the study period from January 2015 to December 2016, a total of 154,387 samples were type and screened for the presence of unexpected antibodies which was included, 74,214 patient samples and 80,173 donor samples. A total of 87,707 male patients and 86,507 female patients were screened; out of 74,214 patient samples, 512 patients (0.20%) were positive for antibody screening and the antibody was also identified. Out of 80,173 donors samples 11 donors (0.004%) were positive for antibody screening and the antibody was also identified. Alloimmunization rate in male patient was 0.19% and in female patient was 0.39% \[Tables [1](#T1){ref-type="table"}-[3](#T3){ref-type="table"}\].

###### 

Results of antibody screening and identification

  Parameters                                                          *n*
  ------------------------------------------------------------------- ---------
  Total number of blood samples underwent type and screen             154,387
  Patient samples                                                     74,214
  Patient samples having antibody screening positive and identified   512
  Donor samples                                                       80,173
  Donor samples having antibody screening positive and identified     11

###### 

Gender-wise distribution of unexpected antibodies

  Parameter                         Gender   Number
  --------------------------------- -------- --------
  Antibody identified in patients   Male     170
  Female                            342      
  Total                             512      
  Antibody identified in donors     Male     11
  Female                            00       
  Total                             11       

###### 

Gender-wise distribution and type of unexpected alloantibodies

  Blood group system                                            Type of antibody   Male patients   Female patients   Male donors   Female donors   Total
  ------------------------------------------------------------- ------------------ --------------- ----------------- ------------- --------------- -------
  Rh                                                            Anti-D             36\*            152^\#^           2             0               190
  Anti-C                                                        2                  2               0                 0             4               
  Anti-c                                                        12                 42              0                 0             54              
  Anti-E                                                        30                 76              0                 0             106             
  Anti-e                                                        1                  5               0                 0             6               
  Anti-C^w^                                                     2                  0               0                 0             2               
  Kell                                                          Anti-K             36              16                0             0               52
  Anti-k                                                        0                  0               0                 0             0               
  Duffy                                                         Anti -Fy^a^        1               0                 0             0               1
  Anti-Fy^b^                                                    2                  0               1                 0             3               
  Kidd                                                          Anti-Jk^a^         2               2                 0             0               4
  Anti-Jk^b^                                                    1                  0               0                 0             1               
  Lewis                                                         Anti-Le^a^         2               0                 0             0               2
  Anti-Le^b^                                                    2                  0               0                 0             2               
  MNS                                                           Anti-M             11              13                1             0               25
  Anti-N                                                        4                  4               0                 0             8               
  Anti-S                                                        8                  10              0                 0             18              
  Anti-s                                                        0                  7               0                 0             7               
  Bombay blood group                                            Anti-H             0               2                 7             0               9
  Multiple antibodies/antibody against high-frequency antigen                      18              11                0             0               29

\*All Rh "D-" positive child of Rh"D-" negative mother (age \<1 month), ^\#^All Rh"D-" negative female patients

Two hundred and fifty patient samples with suspected autoantibody or autoantibody with underlying alloantibody were excluded from the present study as we were unable to do further immunohematological workup to differentiate between autoantibody and autoantibody with underlying alloantibody.

Most common alloantibody found in the present study is anti-D (0.075%), followed by anti-E (0.041%), anti-c (0.021%), anti-K (0.0205%) in Rh and Kell blood group system. In MNS group, the most common antibody found is anti-M followed by anti-S followed by anti-N\> and anti-s. The other significant alloantibodies such as Anti-Jk^a^, Anti-Jk^b^, Anti-Fy^a^, Anti-Fy^b^, Anti-Lu^a^, and Anti-Lu^b^ were found in lower frequency \[[Table 4](#T4){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}\].

###### 

Frequency and specificities of unexpected alloantibodies identified

  Blood group systems                                           Antibody      *n* (%)       Frequency (%)
  ------------------------------------------------------------- ------------- ------------- ---------------
  Rh                                                            Anti-D        190 (36.32)   0.075
  Anti-C                                                        4 (0.76)      0.0015        
  Anti-c                                                        54 (10.32)    0.021         
  Anti-E                                                        106 (20.26)   0.041         
  Anti-e                                                        6 (1.14)      0.002         
  Anti-C^W^                                                     2 (0.38)      0.0007        
  Kell                                                          Anti-K        52 (9.94)     0.020
  Anti-k                                                        0             0             
  Duffy                                                         Anti -Fy^a^   1 (0.19)      0.0004
  Anti-Fy^b^                                                    3 (0.57)      0.0011        
  Kidd                                                          Anti-Jk^a^    4 (0.76)      0.0015
  Anti-Jk^b^                                                    1 (0.19)      0.0004        
  Lewis                                                         Anti-Le^a^    2 (0.38)      0.0007
  Anti-Le^b^                                                    2 (0.38)      0.0007        
  MNS                                                           Anti-M        25 (4.78)     0.0098
  Anti-N                                                        8 (1.52)      0.0031        
  Anti-S                                                        18 (3.44)     0.0070        
  Anti-s                                                        7 (1.33)      0.0027        
  Bombay blood group                                            Anti-H        9 (1.72)      0.0035
  Multiple antibodies/antibody against high frequency antigen                 29 (5.54)     0.0114
  Total                                                         523                         

![Graphical presentation of frequency of different alloantibodies shown in chart](AJTS-13-34-g001){#F1}

In 29 patient samples, the alloantibodies could not be accurately characterized. These samples contain either multiple alloantibodies or antibody against high-frequency antigen.

As our aim of the study is to identify unexpected antibody in donors and patients, we have included anti-H antibody in the study. However, it was found as naturally occurring antibody in Bombay blood group patients.

Discussion {#sec1-4}
==========

In the present study, a total of 174,214 patient samples and 80,173 donor samples were processed for type and screen as per our routine protocol. Antibody screening was positive in 512 patient\'s (0.20%) and 11 donor\'s samples (0.004%). The present study has excluded 250 patient\'s samples demonstrating autoantibody or autoantibody with underlying alloantibody. The overall alloimmunization rate was 3%. The most frequent unexpected alloantibodies identified were against the Rh antigen system (69.21%), followed by Kell antigen system (9.94%). Anti-D was the most frequent alloantibody (36.32%) identified in the present study due to routine type and screen protocol of all antenatal patients as per our institution policy and may be due to lack of universal Rh immunoprophylaxis of all Rh "D-" negative mothers.\[[@ref3]\]

Fewer studies have been done worldwide on alloimmunization in general patient population. Makroo *et al*. studied a total of 49,077 patient samples for the presence of unexpected antibodies. Antibody screening was positive in 403 patient samples (0.82%). Out of 403 patient samples, 212 patient samples had only alloantibodies suggesting overall alloimmunization rate of 0.49%. Antibody against the Rh system was the most frequent (64.1%), the most common alloantibody identified being anti-E (37.2%) followed by anti-D (19.2%) \[[Table 5](#T5){ref-type="table"}\].\[[@ref4]\] A study done by Chaudhary and Agarwal in total 2026 patient samples for the presence of unexpected antibodies. screening was positive in 26 patient samples. Anti-E was the most frequent alloantibody identified.\[[@ref4][@ref5]\]

###### 

Comparison of different studies

  Study                   Years   Total number of patient samples tested   Positive   Most common alloantibody detected
  ----------------------- ------- ---------------------------------------- ---------- -----------------------------------
  Chaudhary and Agarwal   2011    2026                                     26         Anti-E
  R.N. Makroo             2012    49,077                                   304        Anti-E
  Present study           2016    174,214                                  512        Anti-D

Transfusion-dependent thalassemia patients and patient having anemia requiring transfusion were also shown to have higher alloimmunization rate in the study. Dhawan *et al*. reported 5.64% alloimmunization rate in 319 transfusion-dependent thalassemia patients.

The development of alloantibodies can significantly complicate transfusion therapy and results in difficulties in selection of compatible blood unit. After the introduction of DAT by Coombs in 1945, which added a new dimension to the safety of blood transfusion, there was a rapid increase in the identification of alloantibodies that caused transfusion reactions or hemolytic disease of the newborn. Alloimmunization occurs when an incompatible antigen introduced in an immunocompetent host evokes an immune response. The way the immune system reacts depends on several factors such as type of antigen, dose of antigen exposure, and frequency of antigen in given population. The complications of alloimmunization that may occur are many; some antibodies may become nondetectable over time endangering future transfusions and placing the patient at risk for anamnestic antibody production, which may lead to delayed hemolytic transfusion reactions. They may even present with a delayed transfusion reaction that may go unrecognized and/or be masked by features of their underlying disease.\[[@ref6]\] The frequency of alloantibodies is expected to be relatively low in blood donors compared with patients in hospital requiring blood transfusion; blood donors have a lower average age and are far less likely to have received blood transfusions in the past. The frequency with which particular antibodies are found depends on the sensitivity of testing (usually relatively low in screening healthy donors) and on the ethnic group being tested. The risk of alloimmunization is higher in patients who have received multiple blood transfusions such as patients of thalassemia and other hemoglobinopathies, hematological disorders, renal failure on dialysis and females with bad obstetric history \[[Table 6](#T6){ref-type="table"}\].\[[@ref7][@ref8]\]

###### 

Various clinical conditions encountered during study

  Diagnosis                                Number of cases
  ---------------------------------------- -----------------
  Antenatal cases                          151
  Hemolytic disease of fetus and newborn   11
  Severe anemia                            105
  Thalassemia                              115
  Sickle cell anemia                       43
  Acquired/congenital heart disease        19
  Gallbladder calculus                     2
  Septicemia                               4
  Thrombocytopenia                         4
  Burns                                    2
  Tuberculosis                             3
  Fracture                                 9
  Trauma                                   14
  Preoperative anemia correction           17
  Hemophilia                               3
  Hemet emesis                             2
  Fibroid                                  1
  Liver cirrhosis                          3
  PLHA                                     2
  Renal stone                              2

PLHA=People living with HIV/AIDS

Limited data are available on frequency of unexpected alloantibodies in general patients and blood donors. The rate of alloimmunization in our general patient population was 0.19% and in blood donor was 0.013%. Different studies in general patients have estimated the presence of unexpected alloantibodies against red cell antigens between 0.46% and 2.4%, while studies in multitransfused patients has reported higher frequency for unexpected alloantibodies.\[[@ref7]\]

There are only a few studies for incidence of irregular red cell alloantibody in healthy donors in India. One study done on alloimmunization in donor population, In Makroo *et al*. total of 3073 donors were typed during the study period. The most common Rh antigen observed in the study population was e (98%) followed by D (93.6%), C (87%), c (58%) and E (20%).\[[@ref9]\] A study by Pahuja *et al*. shows incidence of 0.05% in their donor population. In another study, Garg *et al*. found 0.09% prevalence of red cell alloantibody. Although there is a low prevalence in normal healthy donor population, the significance of irregular erythrocyte antibodies can be appreciated only when large amount of plasma or whole blood is transfused as in massive transfusions and in pediatric patients.\[[@ref10]\] In another study on antenatal women performed by Varghese J *et al*. alloimmunization was found in 1.48%. Anti-D was the most frequent antibody found.\[[@ref11]\]

From the results of [Table 5](#T5){ref-type="table"}, we can conclude that the frequency of alloimmunization was higher in antenatal patients, multitransfused patients, for example, thalassemia, and in patients suffering from severe anemia \[[Table 5](#T5){ref-type="table"}\].

Conclusion {#sec1-5}
==========

Red blood cell (RBC) alloimmunization is an immune response against foreign RBC antigens; this generally occurs after sensitization due to blood transfusion and pregnancies. Universal prophylaxis of all Rh "D-" negative mothers during first pregnancy can prevent alloimmunization of Rh "D" mother and subsequent HDFN.

Similarly, Rh, Kell phenotyping of thalassemia patients and multiple transfused patients can help in identifying most suitable blood unit for transfusion and prevent alloimmunization.

Limitation {#sec2-1}
----------

Every sample was first run in Qwalys-3 with screenlys plate and three cell panel, which detect only IgG antibodies, So many IgM alloantibodies would have missed.
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